Krystal Biotech, Inc. (NASDAQ:KRYS) Given Average Rating of “Buy” by Brokerages

Krystal Biotech, Inc. (NASDAQ:KRYSGet Rating) has earned a consensus rating of “Buy” from the eight research firms that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and six have assigned a buy recommendation to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $101.60.

A number of equities analysts recently commented on the stock. Bank of America assumed coverage on shares of Krystal Biotech in a research note on Tuesday, January 18th. They set a “buy” rating and a $110.00 target price for the company. Guggenheim lowered their target price on shares of Krystal Biotech from $114.00 to $101.00 in a research note on Tuesday, March 29th. The Goldman Sachs Group lowered their target price on shares of Krystal Biotech from $125.00 to $93.00 and set a “buy” rating for the company in a research note on Tuesday, March 1st. Zacks Investment Research cut shares of Krystal Biotech from a “hold” rating to a “sell” rating in a research report on Wednesday, March 2nd. Finally, HC Wainwright reduced their price target on shares of Krystal Biotech from $124.00 to $107.00 and set a “buy” rating for the company in a research report on Monday, February 28th.

Shares of KRYS stock opened at $64.21 on Thursday. The firm has a fifty day moving average price of $66.21 and a 200 day moving average price of $61.91. The company has a market cap of $1.62 billion, a P/E ratio of -20.58 and a beta of 0.96. Krystal Biotech has a 12 month low of $38.86 and a 12 month high of $102.99.

Krystal Biotech (NASDAQ:KRYSGet Rating) last issued its earnings results on Monday, February 28th. The company reported ($0.95) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.23). As a group, equities analysts expect that Krystal Biotech will post -4.07 earnings per share for the current fiscal year.

Large investors have recently made changes to their positions in the company. Toronto Dominion Bank purchased a new stake in shares of Krystal Biotech in the fourth quarter valued at about $567,000. CWM LLC purchased a new stake in shares of Krystal Biotech in the fourth quarter valued at about $4,192,000. Marshall Wace LLP purchased a new stake in shares of Krystal Biotech in the third quarter valued at about $1,339,000. SG Americas Securities LLC raised its holdings in shares of Krystal Biotech by 0.6% in the fourth quarter. SG Americas Securities LLC now owns 52,470 shares of the company’s stock valued at $3,670,000 after buying an additional 288 shares during the last quarter. Finally, Rafferty Asset Management LLC raised its holdings in shares of Krystal Biotech by 4.0% in the third quarter. Rafferty Asset Management LLC now owns 23,254 shares of the company’s stock valued at $1,214,000 after buying an additional 892 shares during the last quarter. 77.94% of the stock is owned by institutional investors and hedge funds.

About Krystal Biotech (Get Rating)

Krystal Biotech, Inc, a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa.

Further Reading

Analyst Recommendations for Krystal Biotech (NASDAQ:KRYS)

Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.